Corrigendum: Characterizing the role of monocytes in T cell cancer immunotherapy using a 3D microfluidic model [Front Immunol, 9, (2018), (416)] DOI: 10.3389/fimmu.2018.00416;Characterizing the role of monocytes in T cell cancer immunotherapy using a 3d microfluidic model

Frontiers in Immunology

Volumn 9, Issue MAR, 2018, Pages

  Lee, Sharon Wei Ling ^a,b,c   Adriani, Giulia ^a   Ceccarello, Erica ^b,d   Pavesi, Andrea ^d   Tan, Anthony Tanoto ^e   Bertoletti, Antonio ^e   Kamm, Roger Dale ^a,f   Wong, Siew Cheng ^b,c  

^a SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c AGENCY FOR SCIENCE   (Singapore)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f Massachusetts Institute of Technology   (United States)

Author keywords

Immune checkpoint; Immunotherapy; Microfluidics; Monocytes; PD L1; T cell receptor redirected T cells; Tumor microenvironment

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL AGGREGATION; CELL CULTURE; CELL EXPANSION; CELL INTERACTION; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY ASSAY; ELECTROPORATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IMPEDANCE; MICROFLUIDIC ANALYSIS; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 85042906330     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01719     Document Type: Erratum

References (70)

1. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med (2015) 7:280s7. doi:10.1126/scitranslmed.aaa3643
2. Manzo T, Sturmheit T, Basso V, Petrozziello E, Michelini RH, Riba M, et al. T cells redirected to a minor histocompatibility antigen instruct intratumoral TNFa expression and empower adoptive cell therapy for solid tumors. Cancer Res (2017) 77:658-71. doi:10.1158/0008-5472.CAN-16-0725
3. Miyazaki Y, Fujiwara H, Asai H, Ochi F, Ochi T, Azuma T. Development of a novel redirected T cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Blood (2013) 121:4894-902. doi:10.1182/blood-2012-11-465971
4. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol (2015) 62:486-91. doi:10.1016/j.jhep.2014.10.001
5. Rooney CM, Ng CYC, Loftin S, Smith CA, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 345:9-13. doi:10.1016/S0140-6736(95)91150-2
6. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 348:62-8. doi:10.1126/science.aaa4967
7. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 29:917-24. doi:10.1200/JCO.2010.32.2537
8. Lai YG, Gelfanov V, Gelfanova V, Kulik L, Chu CL, Jeng SW, et al. IL-15 promotes survival but not effector function differentiation of CD8(+) TCR alpha beta(+) intestinal intraepithelial lymphocytes. J Immunol (1999) 163:5843-50
9. Scheffel MJ, Scurti G, Simms P, Garrett-Mayer E, Mehrotra S, Nishimura MI, et al. Efficacy of adoptive T-cell therapy is improved by treatment with the antioxidant N-acetyl cysteine, which limits activation-induced T-cell death. Cancer Res (2016) 76:6006-16. doi:10.1158/0008-5472.CAN-16-0587
10. Tamang DL, Alves BN, Elliott V, Fraser SA, Redelman D, Hudig D. Low dose IL-15 induces snap arming of CD44 low T lymphocytes in the absence of antigen. Cell Immunol (2008) 251:93-101. doi:10.1016/j.cellimm.2008.04.007
11. Gehring AJ, Xue S, Ho ZZ, Teoh D, Ruedl C, Chia A, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol (2011) 55:103-10. doi:10.1016/j.jhep.2010.10.025
12. Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, et al. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis. Mol Ther Nucleic Acids (2013) 2:e114. doi:10.1038/mtna.2013.43
13. Pavesi A, Tan AT, Chen MB, Adriani G, Bertoletti A, Kamm RD. Using microfluidics to investigate tumor cell extravasation and T-cell immunotherapies. Conf Proc IEEE Eng Med Biol Soc (2015) 2015:1853-6. doi:10.1109/EMBC.2015.7318742
14. Pavesi A, Tan AT, Koh S, Chia A, Colombo M, Antonecchia E, et al. A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors. JCI Insight (2017) 2:e89762. doi:10.1172/jci.insight.89762
15. Joyce JA, Fearon DT. T cell exclusion, immune privilege and the tumour microenvironment. Science (2015) 348:74-80. doi:10.1126/science.aaa6204
16. Sharma P, Allison JP. The future of immune checkpoint therapy. Science (2015) 348:56-61. doi:10.1126/science.aaa8172
17. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 18:6580-7. doi:10.1158/1078-0432.CCR-12-1362
18. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res (2009) 15:971-9. doi:10.1158/1078-0432.CCR-08-1608
19. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med (2009) 206:1327-37. doi:10.1084/jem.20082173
20. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol (2008) 45:963-70. doi:10.1016/j.molimm.2007.07.038
21. Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis. Medicine (2015) 94:e515. doi:10.1097/md.0000000000000515
22. Haile ST, Bosch JJ, Agu NI, Zeender M, Somasundaram P, Srivastava MK, et al. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol (2017) 186:6822-9. doi:10.4049/jimmunol.1003682
23. Markwick LJL, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology (2015) 148:590-602. doi:10.1053/j.gastro.2014.11.041
24. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 369:134-44. doi:10.1056/NEJMoa1305133
25. Rajan A, Gulley JL. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res (2014) 3:403-5. doi:10.3978/j.issn.2218-6751.2014.09.02
26. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD-1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2014) 15:69-77. doi:10.1016/S1470-2045(13)70551-5
27. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369:122-33. doi:10.1056/NEJMoa1302369
28. DoseffAI, Parihar A. Monocyte subsets and their role in tumor progression. InTech (2012):43-62. doi:10.5772/32615
29. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 72:3125-30. doi:10.1158/0008-5472.CAN-11-4094
30. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 5:953-64. doi:10.1038/nri1733
31. Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood (2007) 110:587-95. doi:10.1182/blood-2007-01-068031
32. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 66:605-12. doi:10.1158/0008-5472.CAN-05-4005
33. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2008) 66:1-9. doi:10.1016/j.critrevonc.2007.07.004
34. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol (2015) 15:73-86. doi:10.1038/nri3789
35. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 141:39-51. doi:10.1016/j.cell.2010.03.014
36. Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol (2017) 19:796-807. doi:10.1093/neuonc/now287
37. Huang R, Francois A, Mcgray AJR, Miliotto A, Huang R, Francois A, et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology (2017) 6:e1249561. doi:10.1080/2162402X.2016.1249561
38. Tan-Garcia A, Wai LE, Zheng D, Ceccarello E, Jo J, Banu N, et al. Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. J Hepatol (2017) 67:490-500. doi:10.1016/j.jhep.2017.04.023
39. Teng Y, Shen Z, Kao C, Tsai T. Hepatocellular carcinoma mouse models: hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 22:300-25. doi:10.3748/wjg.v22.i1.300
40. Wilson EM, Bial J, Tarlow B, Bial G, Jensen B, Greiner DL, et al. Extensive double humanization of both liver and hematopoiesis in FRGN mice. Stem Cell Res (2014) 13:404-12. doi:10.1016/j.scr.2014.08.006
41. Rodenhizer D, Dean T, D'Arcangelo E, McGuigan AP. The current landscape of 3D in vitro tumor models: what cancer hallmarks are accessible for drug discovery? Adv Healthc Mater (2018) 1701174. doi:10.1002/adhm.201701174
42. Adriani G, Ma D, Pavesi A, Goh ELK, Kamm RD. Modeling the blood-brain barrier in a 3D triple co-culture microfluidic system. Conf Proc IEEE Eng Med Biol Soc (2015) 2015:338-41. doi:10.1109/EMBC.2015.7318368
43. Adriani G, Pavesi A, Tan AT, Bertoletti A, Thiery JP, Kamm RD. Microfluidic models for adoptive cell-mediated cancer immunotherapies. Drug Discov Today (2016) 21:1472-8. doi:10.1016/j.drudis.2016.05.006
44. Adriani G, Ma D, Pavesi A, Kamm RD. A 3D neurovascular microfluidic model consisting of neurons, astrocytes and cerebral endothelial cells as a blood-brain barrier. Lab Chip (2017) 17:448-59. doi:10.1039/C6LC00638H
45. Boussommier-Calleja A, Li R, Chen MB, Wong SC, Kamm RD. Microfluidics: a new tool for modeling cancer-immune interactions. Trends Cancer (2016) 2:6-19. doi:10.1016/j.trecan.2015.12.003
46. Ho YT, Adriani G, Beyer S, Nhan PT, Kamm RD, Kah JCY. A facile method to probe the vascular permeability of nanoparticles in nanomedicine applications. Sci Rep (2017) 7:707. doi:10.1038/s41598-017-00750-3
47. Pavesi A, Adriani G, Tay A, Warkiani ME, Yeap WH, Wong SC, et al. Engineering a 3D microfluidic culture platform for tumor-treating field application. Sci Rep (2016) 6:26584. doi:10.1038/srep26584
48. Penny HL, Sieow JL, Adriani G, Yeap WH, See Chi Ee P, San Luis B, et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. Oncoimmunology (2016) 5:e1191731. doi:10.1080/2162402X.2016.1191731
49. Tay A, Pavesi A, Yazdi SR, Lim CT, Warkiani ME. Advances in microfluidics in combating infectious diseases. Biotechnol Adv (2016) 34:404-21. doi:10.1016/j.biotechadv.2016.02.002
50. Tu T, Wang Z, Bai J, Sun W, Peng WK, Huang RY, et al. Rapid prototyping of concave microwells for the formation of 3D multicellular cancer aggregates for drug screening. Adv Healthc Mater (2014) 3:609-16. doi:10.1002/adhm.201300151
51. Adriani G, Bai J, Wong S, Kamm RD, Thiery JP. M2a macrophages induce contact-dependent dispersion of carcinoma cell aggregates. Macrophage (2016) 3:e1222. doi:10.14800/macrophage.1222
52. Bai J, Adriani G, Dang TM, Tu TY, Penny HXL, Wong SC, et al. Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and ß2 integrin interactions. Oncotarget (2015) 6:25295-307. doi:10.18632/oncotarget.4716
53. Aref AR, Huang RYJ, Yu W, Chua KN, Sun W, Tu TY, et al. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. Integr Biol (2013) 5:381-9. doi:10.1039/c2ib20209c
54. Shin Y, Han S, Jeon JS, Yamamoto K, Zervantonakis IK, Sudo R, et al. Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels. Nat Protoc (2012) 7:1247-59. doi:10.1038/nprot.2012.051
55. Moreno-Cubero E, Larrubia JR. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol (2016) 22:6469-83. doi:10.3748/wjg.v22.i28.6469
56. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, et al. PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer (2011) 128:887-96. doi:10.1002/ijc.25397
57. Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology (2017) 153(4):1107.e-19.e. doi:10.1053/j.gastro.2017.06.017
58. Brentjens R, Davila ML, Riviere I, Park J, Cowell LG, Bartido S, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 5:177ra38. doi:10.1126/scitranslmed.3005930
59. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 368:1509-18. doi:10.1056/NEJMoa1215134
60. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2015) 33:540-9. doi:10.1200/JCO.2014.56.2025
61. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2015) 385:517-28. doi:10.1016/S0140-6736(14)61403-3
62. Maude SL, Frey NV, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 371:1507-17. doi:10.1056/NEJMoa1407222
63. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 8:793-800. doi:10.1038/nm730
64. Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J (2014) 20:265-71. doi:10.1097/PPO.0000000000000059
65. Sauce D, Almeida JR, Larsen M, Haro L, Autran B, Freeman GJ, et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS (2007) 21:2005-13. doi:10.1097/QAD.0b013e3282eee548
66. Kinter AL, Godbout EJ, Mcnally JP, Sereti I, Roby GA, Shea MAO, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol (2008) 181:6738-46. doi:10.4049/jimmunol.181.10.6738
67. Dit Faute MA, Laurent L, Ploton D, Poupon M. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis (2002) 19(2):161-8. doi:10.1023/A:1014594825502
68. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, et al. Engineering tumors with 3D scaffolds. Nat Methods (2007) 4:855-60. doi:10.1038/nmeth1085
69. Görlach A, Herter P, Hentschel H, Frosch PJ, Acker H. Effects of nIFN beta and rIFN gamma on growth and morphology of two human melanoma cell lines: comparison between two-and three-dimensional culture. Int J Cancer (1994) 56:249-54. doi:10.1002/ijc.2910560218
70. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen (2004) 9:273-85. doi:10.1177/1087057104265040